Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health exploratory trials in Parkinson disease (NET-PD) experience

Archives of Neurology

Volumn 66, Issue 9, 2009, Pages 1099-1104

  Parashos, Sotirios A ^a   Swearingen, Christopher J ^b   Biglan, Kevin M ^c   Bodis Wollner, Ivan ^d   Liang, Grace S ^e   Ross, G Webster ^f   Tilley, Barbara C ^b   Shulman, Lisa M ^g  

^a Struthers Parkinson's Center   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e PARKINSON S INSTITUTE   (United States)

^f PACIFIC HEALTH RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CREATININE; DOPAMINE RECEPTOR BLOCKING AGENT; GPI 1485; LEVODOPA; MINOCYCLINE; SELEGILINE; UBIDECARENONE;

ADULT; ARTICLE; CANADA; CONTROLLED STUDY; DEPRESSION; DISABILITY; DISEASE DURATION; EDUCATIONAL STATUS; ETHNICITY; FEMALE; FUNCTIONAL STATUS; GERIATRIC DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RACE; RANKIN SCALE; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; UNITED KINGDOM; UNITED STATES;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ANTIPARKINSON AGENTS; CREATINE; DISABILITY EVALUATION; DISEASE MANAGEMENT; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; MOBILITY LIMITATION; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TIME FACTORS; UBIQUINONE;

EID: 70349114683     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.159     Document Type: Article

References (22)

1. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner W; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):968-975. (Pubitemid 44044779)
2. Parashos SA, Maraganore DM, O'Brien PC, Rocca WA. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin Proc. 2002;77(9):918-925. (Pubitemid 34977634)
3. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58(1):11-17. (Pubitemid 34041931)
4. Elm JJ, Goetz CG, Ravina B, et al; NET-PD Investigators. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005;57(2):197-203.
5. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol. 1989;46(10):1052-1060. (Pubitemid 19246292)
6. Shults CW, Oakes D, Kieburtz K, et al; Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541-1550.
7. LeWitt P, Oakes D, Cui L; Parkinson Study Group. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and a-tocopherol. Mov Disord. 1997;12(2):183-189. (Pubitemid 27152022)
8. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66(5):664-671.
9. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson's disease. Neurology. 2007;68(1):20-28.
10. Fahn S, Elton RL; Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CO, Calne DB, Goldstein M, eds. Recent Development in Parkinson's Disease. Florham Park, NJ: Macmillan Health Care Information; 1987:153-164.
11. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap stroke patients. Stroke. 1988;19(5):604-607.
12. Schwab RS, England ACJ. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IML, eds. Third Symposium on Parkinson's Disease. Edinburgh, Scotland: E & S Livingstone; 1969:152-157.
13. Shoulson I, Kurlan R, Rubin A, et al. Assessment of functional capacity in neurodegenerative disorders: Huntington's disease as a prototype. In: Munsat TL, ed. Quantification of Neurologic Deficit. Boston, MA: Butterworth; 1989:271-283.
14. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing. 1997;26(5):353-357. (Pubitemid 27448379)
15. Ware JE Jr, Kosinski M, Turner-Bowker DM, Gandek B. How to Score Version 2 of the SF-12 Health Survey (With a Supplement Documenting Version 1). Lincoln, RI: QualityMetric Inc; 2002.
16. Meara J, Mitchelmore E, Hobson P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their careers in the community. Age Ageing. 1999;28(1):35-38. (Pubitemid 29084060)
17. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: Wiley; 1989.
18. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-387.
19. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321(20):1364-1371. (Pubitemid 19284193)
20. McDermott MP, Jankovic J, Carter J, et al; The Parkinson Study Group. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. Arch Neurol. 1995;52(6):565-570.
21. Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Young- versus older-onset Parkinson's disease: impact of disease and psychosocial consequences. Mov Disord. 2003;18(11):1250-1256. (Pubitemid 38263307)
22. Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69(4):342-347. (Pubitemid 47205660)